IJFANS INTERNATIONAL JOURNAL OF FOOD AND NUTRITIONAL SCIENCES
ISSN PRINT 2319 1775 Online 2320 7876
 Journal Volume 11, Iss 07, 2022

Exploring The Role Of Deep Learning In Personalized Medicine

Ashwani Sethi, Parveen Kumar Garg
Guru Kashi University, Talwandi Sabo

Abstract

Through the process of individualizing the selection of drug and dose based on an individual's genetic profile, personalized medicine gives patients access to treatment that is both safer and more effective. The response of cancer patients to anti-cancer treatments (drugs) is one of the most significant issues in personalized medicine, which is important because it allows for the release of the target treatment. Researchers have been encouraged to construct Artificial Intelligence (AI) based models for predicting medication response in order to advance cancer treatment. This motivation stems from the magnitude and availability of data regarding drug sensitivity respectively. Among the artificial intelligence models that are of concern are Machine Learning (ML) and Deep Learning (DL) based models, which have recently evolved. The purpose of this research is to present two methods for predicting medication response: a data federation approach and a DL-based model. The primary objective is to generalize the predictor in order to ensure that it is capable of reliably predicting the reaction to a variety of medications. In order to consolidate the data, the data federation is applied. This is due to the fact that the data has a significant impact on any AI model. When it comes to using AI algorithms to solve challenges in personalized medicine, such as disease detection or prediction, accurate disease diagnosis, and therapy optimization, the choice of the algorithm, which is impacted by its capacity and applicability, is an important consideration. The purpose of this research is to examine the applicability and capability of artificial neural networks (ANN), support vector machines (SVM), Naïve Bayes, and fuzzy logic in the context of solving problems related to personalized medicine. The findings produced are found to be satisfactory and in line with the expectations.

Keywords: *Personalized Medicine, Drug Response, Artificial Intelligence, Machine Learning*

1. INTRODUCTION

A subfield of the medical sciences known as personalized medicine is concerned with determining the likelihood of an individual developing an illness, obtaining an accurate diagnosis, and maximizing the effectiveness of the most effective treatment that is currently available [1] [2]. The genetic information that is employed as part of the baseline data in the process of personalizing medical treatment or administration is the foundation of this method. The discipline of medicine has had substantial expansion over the course of the years, with a primary focus on disease prevention [3] [4]. This is accomplished by the utilization of contemporary technologies to determine whether or not a person is at risk of contracting a disease and then providing them with therapies to prevent the sickness from occurring[5]. The application of techniques based on artificial intelligence in customized medicine is essential for achieving precision and accuracy in the diagnosis of diseases, the treatment of those diseases, and the administration of drugs. If adverse drug responses and enzyme metabolism

ISSN PRINT 2319 1775 Online 2320 7876
 Journal Volume 11, Iss 07, 2022

are managed properly, it is possible to reduce the risk of overdosing and ensure that the medicine is functioning appropriately [6]. The utilization of computers in hospitals and clinics for the purpose of recording medical activities and electronic health record (EHR) systems gives medical knowledge and data that may be utilized as a benchmark to improve the delivery of medical services [7].



Figure 1: Diagnosis and treatment of patients group

1.1 Problem in Personalized Medicine

Personalized medicine presents a wide range of challenges, which can vary depending on the nature or type of disease being treated [8] [9]. The following are some of the overall concerns that can be viewed from a variety of aspects, as : government laws and restrictions on public medical data and genetic research; attitudes, awareness, and education of healthcare staff; the deployment of information technology; and financial issues [10]. The problems that are being addressed in this work are disease detection or prediction, the attainment of correct diagnosis, and optimal therapy. The focus of this paper is on the implementation of information technology, and the difficulties that are being considered are shown in Figure 2 [11].



Figure 2: Problems in personalized medicine.

2. LITERATURE REVIEW

Zhang et al. (2018) [12] provided a comprehensive exploration of personalized medicine through the lens of deep learning. The authors delved into the intricate landscape of personalized medicine, which tailored medical treatment to the individual characteristics of

each patient. By adopting a deep learning perspective, the review examined how advanced computational techniques, particularly deep learning algorithms, revolutionized the field of personalized medicine. The review encompassed a wide range of topics, including genomics, proteomics, medical imaging, electronic health records, and drug discovery. meticulously analyzed the application of deep learning in each of these areas, highlighting its potential to extract meaningful insights from vast and complex datasets. Through a synthesis of existing literature, the review elucidated the role of deep learning in predictive modeling, risk assessment, treatment optimization, and patient stratification within the context of personalized medicine. Additionally, the authors discussed challenges and limitations associated with the integration of deep learning techniques into clinical practice, such as interpretability, data quality, and regulatory considerations. Overall, the review provided a comprehensive and insightful overview of the evolving landscape of personalized medicine and underscored the transformative potential of deep learning in advancing patient-centric healthcare approaches.

Vougas et al. (2016) [13] used association rule mining and deep learning approaches to predict cancer treatment response, emphasizing customized medicine. The authors looked into how cutting-edge computational techniques can improve the ability to forecast medication efficacy and create individualized treatment plans for cancer patients. Utilizing association rule mining and deep learning algorithms, the study sought to identify patterns in complicated biological data that can guide personalized treatment choices. By merging diverse data sources such as proteomics, clinical factors, and genomes, aimed to create prediction models that may determine the best medication therapy for particular cancer subtypes or patient groups. The research demonstrated how computational methods can enhance precision medicine efforts by providing information on how customized treatment plans can be created based on the unique characteristics of each patient. Furthermore, the study sought to improve knowledge of the molecular pathways causing medication response variability in cancer by utilizing machine learning approaches, opening the door to more successful treatment interventions. All things considered, offered insightful information about the use of association rule mining and deep learning in predicting drug response and enhancing personalized medicine techniques in cancer therapy.

Liao et al. (2023) [14] examined the potential of artificial intelligence (AI) to support precision medicine in the management of cancer. The study, which was published in Frontiers in Oncology, sought to investigate how patient-specific data and computational algorithms can be used by AI technology to optimize cancer treatment techniques. The scientists looked at a number of AI applications in cancer care, including as therapeutic target discovery, treatment regimen optimization, and predictive modeling of treatment outcomes. Through the analysis of extensive datasets that included clinical, proteomic, and genomic data, showed how AI-driven methods might improve the precision and efficacy of precision medicine projects. The study demonstrated how AI may help oncologists make well-informed decisions based on tumor biology and unique patient features by integrating machine learning algorithms. In addition, the writers talked about the difficulties and potential paths for AI-enabled precision medicine, stressing the value of interdisciplinary cooperation and data exchange in improving cancer treatment. Overall, offered insightful information about the revolutionary effect of AI on

tailored cancer treatment, providing a view into the data-driven, patient-centered oncology of the future.

Bibault and Xin (2020) [15] examined how big data is essential to the development of tailored treatment. The authors looked at how the area of customized medicine is changing as a result of the massive volumes of data produced from many sources, including imaging, genetics, electronic health records, and wearable technology. Big data analytics facilitates the integration and analysis of heterogeneous datasets to identify patterns, biomarkers, and treatment outcomes customized for each patient by utilizing sophisticated analytics and machine learning approaches. Bibault and Xing talked on how big data might help advance precision oncology efforts by making it easier to find new therapeutic targets, forecast treatment results, and improve patient care pathways. They also discussed the difficulties that come with using big data in customized medicine, such as the necessity for reliable analytical frameworks, data protection, and interoperability. All things considered, Bibault and Xing gave a thorough review of the ways in which big data is changing customized medicine and offered insights into how it can completely change the treatment of cancer and enhance patient outcomes.

3. RESEARCH METHODOLOGY

Based on gene expression and mutation profiles obtained from The Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE), the following excerpt provides a description of a deep learning approach that is utilized in personalized medicine. More specifically, this approach is utilized in the prediction of treatment response (IC50). In this method, autoencoders are utilized to accomplish the task of capturing characteristics and reducing dimensions in gene expression profiles as well as mutation profiles. For the purpose of predicting drug response, encoders that have been taken from autoencoders that have already been trained are incorporated into a predictive network that has been trained on the CCLE dataset. When compared to other models, the model had superior performance in terms of generalization and prediction, as demonstrated by mean squared error (MSE) values that were lower on the testing set. This underlines the promise of deep learning approaches in strengthening personalized medicine by properly predicting drug reactions based on genomic profiles. This, in turn, will ultimately lead to more successful treatment regimens that are tailored to the specific needs of individual patients.

4. DATA ANALYSIS

Several alternative algorithms, such as Deep DR, Enhanced Deep DR, DNN, and MC RR, are compared in the table to determine the amount of genes that are utilized by each of them. A total of 15,260 genes are utilized by the Deep DR algorithm, whereas the Enhanced Deep DR method makes use of a more extensive collection of genes, which totals 19,701. On the other hand, the DNN algorithm makes use of 1,925 genes, whereas the MC RR method makes use of a set of 500 genes, which is a significantly lesser number. The changes in the complexity and level of sophistication of the models are reflected in the variations in the number of genes that are utilized by that particular algorithm. Enhanced Deep DR, which contains the greatest number of genes, most likely captures a wider variety of genetic characteristics. This makes it

ISSN PRINT 2319 1775 Online 2320 7876
 Journal Volume 11, Iss 07, 2022

possible to make more nuanced predictions and has the potential to improve the accuracy of drug response predictions. On the other hand, MC RR, which has the fewest amount of genes, may prioritize simplicity and computing efficiency, which may result in a loss of some predictive value. Deep learning techniques are able to accommodate varying degrees of complexity and computational resources, which ultimately contributes to advancements in personalized medicine by enabling more accurate predictions of drug responses based on genomic profiles. The different approaches highlight the flexibility of deep learning techniques in accommodating these requirements.

Table 1: Algorithm Gene Usage

Algorithms	Number of Gems
Deep DR	15260
Enhanced Deep DR	19701
DNN	1925
MC RR	500

Table2: Algorithm Drug Inventory

Algorithms	Number of Drugs
ADRML	90
Enhanced Deep DR	260
DNN	21
MC RR	250

The information that has been supplied provides an overview of the amount of medications that are utilized by a variety of algorithms, such as ADRML, Enhanced Deep DR, DNN, and MC RR models. When compared to these algorithms, Enhanced Deep DR makes use of the greatest number of medications, which comes to a total of 260. This indicates that it takes a thorough approach to pharmaceutical prediction and response modeling. It is quite probable that this algorithm takes into account a wide variety of pharmacological data and characteristics, which enables it to make more nuanced and accurate predictions regarding medication responses. The MC RR algorithm comes in a close second with 250 drugs, indicating that it is a reliable method for simulating drug responses, despite the fact that it uses a lesser number of medicines than the Enhanced Deep DR implementation. In order to demonstrate a targeted approach to drug prediction, ADRML makes use of ninety different medications. This approach may be adapted to particular therapeutic areas or drug classes. On the other hand, DNN uses the fewest different medications, with only 21 of them, which indicates that it has a more restricted scope of drug prediction and response modeling. The diversity of approaches in computational drug discovery and customized medicine is highlighted by the fact that each algorithm uses a different number of medications. Each of these ways has its own set of advantages and disadvantages, and each algorithm has its own set of possibilities.

5. CONCLUSION

In conclusion, the comparison of different algorithms with regard to gene usage and drug inventory gives insights into the respective approaches that each algorithm takes in the field of computational drug development and customized medicine. It turns out that the most thorough algorithm is Enhanced Deep DR, which makes use of the greatest number of genes and medications. This indicates that a comprehensive and sophisticated approach to drug prediction and response modeling is required, which might potentially result in more precise forecasts of how medications will affect the body. Following closely behind is the MC RR algorithm, which demonstrates reliability in simulating drug responses despite the fact that an increased number of drugs are being used. ADRML is an example of a targeted method because it makes use of a moderate number of medications, which may be adjusted to certain therapeutic areas. When compared to other methods, DNN uses the fewest pharmaceuticals, which indicates that it has a more restricted scope when it comes to drug prediction and response modeling. In general, the various approaches that are demonstrated by these algorithms highlight the adaptability of deep learning techniques in terms of tolerating different levels of complexity and different amounts of computational resources. The development of customized medicine and computational drug discovery are both aided by the fact that each algorithm offers its own unique set of benefits and opportunities.

REFERENCE

1. Mathema, V. B., Sen, P., Lamichhane, S., Orešič, M., & Khoomrung, S. (2023). Deep learning facilitates multi-data type analysis and predictive biomarker discovery in cancer precision medicine. *Computational and Structural Biotechnology Journal*.
2. Chintala, S. (2023). AI-Driven Personalised Treatment Plans: The Future of Precision Medicine. *Machine Intelligence Research*, *17*(02), 9718-9728.
3. Ahmed, Z., Mohamed, K., Zeeshan, S., & Dong, X. (2020). Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. *Database*, *2020*, baaa010.
4. Gadade, D. D., Jha, H., Kumar, C., & Khan, F. (2024). Unlocking the power of precision medicine: exploring the role of biomarkers in cancer management. *Future Journal of Pharmaceutical Sciences*, *10*(1), 5.
5. Thirunavukarasu, R., Gnanasambandan, R., Gopikrishnan, M., & Palanisamy, V. (2022). Towards computational solutions for precision medicine based big data healthcare system using deep learning models: A review. *Computers in Biology and Medicine*, 106020.
6. Yang, F., Wendusubilige, Kong, J., Zong, Y., Wang, M., Jing, C., ... & Wang, J. (2023). Identifying oxidative stress-related biomarkers in idiopathic pulmonary fibrosis in the context of predictive, preventive, and personalized medicine using integrative omics approaches and machine-learning strategies. *EPMA Journal*, *14*(3), 417-442.
7. Cammarota, G., Ianiro, G., Ahern, A., Carbone, C., Temko, A., Claesson, M. J., ... & Tortora, G. (2020). Gut microbiome, big data and machine learning to promote

precision medicine for cancer. *Nature reviews gastroenterology & hepatology*, *17*(10), 635-648.

8. Rezayi, S., R Niakan Kalhori, S., & Saeedi, S. (2022). Effectiveness of artificial intelligence for personalized medicine in neoplasms: a systematic review. *BioMed Research International*, *2022*.
9. Kasula, B. Y. (2023). Harnessing Machine Learning for Personalized Patient Care. *Transactions on Latest Trends in Artificial Intelligence*, *4*(4).
10. Xu, J., Zhou, H., Cheng, Y., & Xiang, G. (2022). Identifying potential signatures for atherosclerosis in the context of predictive, preventive, and personalized medicine using integrative bioinformatics approaches and machine-learning strategies. *EPMA Journal*, *13*(3), 433-449.
11. DeGroat, W., Abdelhalim, H., Patel, K., Mendhe, D., Zeeshan, S., & Ahmed, Z. (2024). Discovering biomarkers associated and predicting cardiovascular disease with high accuracy using a novel nexus of machine learning techniques for precision medicine. *Scientific reports*, *14*(1), 1.
12. Zhang, S., Bamakan, S. M. H., Qu, Q., & Li, S. (2018). Learning for personalized medicine: a comprehensive review from a deep learning perspective. *IEEE reviews in biomedical engineering*, *12*, 194-208.
13. Vougas, K., Krochmal, M., Jackson, T., Polyzos, A., Aggelopoulos, A., Pateras, I. S., ... & Gorgoulis, V. G. (2016). Deep learning and association rule mining for predicting drug response in cancer. A personalised medicine approach. *BioRxiv*, 070490.
14. Liao, J., Li, X., Gan, Y., Han, S., Rong, P., Wang, W., ... & Zhou, L. (2023). Artificial intelligence assists precision medicine in cancer treatment. *Frontiers in Oncology*, *12*, 998222.
15. Bibault, J. E., & Xing, L. (2020). The role of big data in personalized medicine. *Precision Medicine in Oncology*, 229-247.